AbbVie Inc (ABBV)vsIntelligent Bio Solutions Inc. (INBS)
ABBV
AbbVie Inc
$253.44
-0.44%
HEALTHCARE · Cap: $441.54B
INBS
Intelligent Bio Solutions Inc.
$1.97
-6.68%
HEALTHCARE · Cap: $5.50M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 1605169% more annual revenue ($62.82B vs $3.91M). ABBV leads profitability with a 5.8% profit margin vs -296.8%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
INBS
Hold38
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-66.2%
Fair Value
$146.91
Current Price
$253.44
$106.53 premium
Margin of Safety
-26.5%
Fair Value
$4.15
Current Price
$1.97
$2.18 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Generating 3.6B in free cash flow
Reasonable price relative to book value
Revenue surging 45.5% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -170.2% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bull Case : INBS
The strongest argument for INBS centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 45.5% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 123.7x leaves little room for execution misses.
Bear Case : INBS
The primary concerns for INBS are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
ABBV profiles as a value stock while INBS is a hypergrowth play — different risk/reward profiles.
INBS carries more volatility with a beta of 4.17 — expect wider price swings.
INBS is growing revenue faster at 45.5% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 38/100) and 12.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Intelligent Bio Solutions Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Intelligent Bio Solutions Inc. (INBS) is a cutting-edge biotechnology company focused on pioneering advanced diagnostic solutions and biomarker-driven technologies specifically designed for drug abuse testing and monitoring. By leveraging innovative scientific methodologies, INBS provides rapid and precise testing options that facilitate timely clinical decision-making and enhance patient outcomes. As the healthcare landscape increasingly demands sophisticated diagnostic tools, INBS is well-positioned to spearhead advancements in healthcare diagnostics, reaffirming its dedication to elevating healthcare quality and operational efficiency.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?